Hua Lin

Dr. Hua Lin


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Orthopaedic Surgery
Verified
Journal Article
Closed access
PDF file
YDYue Ding
Yue Ding
JZJian‐Cheng Zeng
Jian‐Cheng Zeng
FYFei Yin
Fei Yin
CZChun‐Lin Zhang
Chun‐Lin Zhang
YZYan Zhang
Yan Zhang
FPFu‐Xing Pei
Fu‐Xing Pei

2 August 2019 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
WXWeibo Xia
Weibo Xia
CCCyrus Cooper
Cyrus Cooper
MLMei Li
Mei Li
LXLing Xu
Ling Xu
RRRene Rizzoli
Rene Rizzoli
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster
Healthy aging is defined as the process of developing and maintaining the functional ability that enables wellbeing in older age. Healthy aging is dependent upon intrinsic capacity, a composite of physical and mental capacities, and the environment an individual inhabits and their interactions with it. Maintenance of musculoskeletal health during aging is a key determinant of functional ability. Sarcopenia, osteoporosis and osteoarthritis, are a triad of musculoskeletal diseases of aging that are major contributors to the global burden of disease and disability worldwide. The prevention and management of these disorders is of increasing importance with pressure mounting from the aging population. In a new initiative, the Chinese Medical Association, Chinese Society of Osteoporosis and Bone Mineral Research, and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases jointly organized a symposium to discuss current practices and policies in the management of musculoskeletal aging. The meeting allowed experts from Europe and China to share their experience and recommendations for the management of these three major diseases. Discussing and analyzing similarities and differences in their practice should lead, through a mutual enrichment of knowledge, to better management of these diseases, in order to preserve intrinsic capacity and retard the age-related degradation of physical ability. In future, it is hoped that sharing of knowledge and best practice will advance global strategies to reduce the burden of musculoskeletal disease and promote healthy aging tailored to meet the individual patient’s needs.

19 January 2023 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
MZMiao Zheng
Miao Zheng
YWYanan Wan
Yanan Wan
GLGongwen Liu
Gongwen Liu
YGYan Gao
Yan Gao
XPXiaoqun Pan
Xiaoqun Pan
HLHua Lin
Hua Lin
Background: Bone mineral density (BMD) and prevalence of osteoporosis may differ between urban and rural populations. This study aimed to investigate the differences in BMD characteristics between urban and rural populations in Jiangsu, China.Methods: A total of 2,711 participants aged 20 years and older were included in the cross-sectional study. Multistage and stratified cluster random sampling was used as the sampling strategy. BMD was measured by the method of dual-energy x-ray absorptiometry (DXA). Data were collected through questionnaires/interview. BMD values at the lumbar spine (L1-L4), femoral neck, total hip, and greater trochanter were collected. Descriptive statistics were used to demonstrate the characteristics of urban and rural participants. Multivariate logistic regression analysis was utilized to analyze the factors that may be associated with osteoporosis in urban and rural populations.Results: Of these participants, 1,540 (50.49%) were females and 1,363 (42.14%) were from urban. The prevalence of osteoporosis in urban and rural populations was 5.52% and 10.33%, respectively. In terms of gender, the prevalence of osteoporosis was 2.68% in males and 13.82% in females. For menopausal status, the prevalence of osteoporosis was 30.34% in postmenopausal females and 4.78% in premenopausal females. In urban populations, older age [adjusted odds ratio (AOR) = 2.36, 95%CI, 2.35–2.36), hypertension (AOR = 1.37, 95%CI, 1.36–1.37), unmarried (AOR = 4.04, 95%CI, 3.99–4.09), smoking everyday (AOR = 2.26, 95%CI, 2.23–2.28), family history of osteoporosis (AOR = 1.66, 95%CI, 1.65–1.67), dyslipidemia (AOR = 1.05, 95%CI, 1.04–1.05), and higher β-crosslaps (β-CTX) level (AOR = 1.02, 95%CI, 1.02–1.02) were associated with an increased risk of osteoporosis, while males (AOR = 0.04, 95%CI, 0.04–0.04), higher education level (AOR = 0.95, 95%CI, 0.95–0.95), and aquatic product intake (AOR = 0.99, 95%CI, 0.99–0.99) were related to decreased risk of osteoporosis. Similar results were also observed in rural populations, and (allP < 0.05).Conclusion: The prevalence of osteoporosis in rural populations was higher than that in urban populations, and the factors associated with the risk of osteoporosis were similar in urban and rural populations.

1 May 2010 in Orthopaedic Surgery
Verified
Journal Article
Closed access
PDF file
HLHua Lin
Hua Lin
LBLi-Hua Bao
Li-Hua Bao
XZXiu-Fen Zhu
Xiu-Fen Zhu
CQCheng Qian
Cheng Qian
XCXin Chen
Xin Chen
ZHZu-Bin Han
Zu-Bin Han

3 July 2018 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
ELEr-Yuan Liao
Er-Yuan Liao
ZZZhen-Lin Zhang
Zhen-Lin Zhang
WXWeibo Xia
Weibo Xia
HLHua Lin
Hua Lin
QCQun Cheng
Qun Cheng
LZLei Zhang
Lei Zhang
Vitamin D (VD) insufficiency or deficiency is a frequent comorbidity in Chinese women with postmenopausal osteoporosis (PMO). The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600). Chinese PMO women (n = 219) were treated with 12-month ALN/D5600 (n = 111) or calcitriol (n = 108). Changes in 25(OH) D at month 12 were post hoc analyzed by the baseline 25 (OH) D status using the longitudinal analysis. The main safety outcome measures included serum calcium and phosphate and 24-h urine calcium, and the repeated measures mixed model was used to assess the frequencies of the calcium-phosphate metabolic disorders. Absolute change in mean serum 25(OH) D level was the greatest in VD-deficient patients and least in VD-sufficient patients at months six and 12 (both, P < 0.01). Serum calcium level remained significantly lower in the ALN/D5600 treatment group than in the calcitriol treatment group throughout the 12 months. Mean 24-h urine calcium slightly increased in the ALN/D5600 treatment group and significantly increased in the calcitriol treatment group (+ 1.1 and + 0.9 mmol/L at months six and 12; both, P < 0.05). Calcitriol treatment was associated with more frequent hypercalciuria at month six (9.4% vs. 18.5%, P = 0.05), but not at month 12 (12.3% vs. 13.0%). Baseline VD status predicted 25(OH) D improvement in PMO patients on 12-month ALN/D5600 treatment. The daily use of 0.25 μg of calcitriol was associated with more frequent hypercalciuria at month six, compared to ALN/5600 treatment, necessitating the safety re-evaluation of calcitriol at a higher dosage.

6 May 2014 in Endokrynologia Polska
Verified
Journal Article
Open access
SHShushu Huang
Shushu Huang
HLHua Lin
Hua Lin
XZXiufen Zhu
Xiufen Zhu
XCXin Chen
Xin Chen
LFLu Fan
Lu Fan
CLChangchang Liu
Changchang Liu
Osteoporosis is characterised by decreased bone mass and weakened bones, with an increased risk of fractures. Osteoporotic fracture, the most serious complication of osteoporosis, is related not only to lower bone mineral density (BMD), but also falls. Osteoporosis and fractures are associated with a decreased health-related quality of life (HRQL). Zoledronic acid (ZOL) is an intravenous once-yearly bisphosphonate that has been shown to be effective and safe in improving BMD and reducing fracture risk in controlled clinical trials. In this self-controlled, prospective trial, 220 postmenopausal women with osteoporosis (mean age 67 years) received a single infusion of ZOL 5 mg at baseline and month 12. BMD, HRQL and Fall Index (FI) were measured at baseline, and months 12 and 24 (before each use of ZOL). The main outcome measures were the changes in lumbar spine and hip BMD and the changes in HRQL, the Short Form-36 questionnaire (SF-36). Additional comparisons were based on the FI. LSD multiple comparisons were used in the comparisons of BMD, SF-36 domain scores and FI. The patients had significantly higher L1-4, total hip, femoral neck and trochanter BMD (P < 0.05) with improved HRQL (P < 0.05) over two years of treatment of once-yearly ZOL 5mg. FI was reduced (P < 0.05) with oral daily elemental calcium and vitamin D in the treatment course. ZOL improves BMD and HRQL, especially in the physical aspects, over two years of treatment in women with postmenopausal osteoporosis, and can help improve balance ability.